Average Sales Price Reimbursement Not Affecting Roche Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche has not seen any change in market dynamics for its products following the switch to an average sales price-based reimbursement model for Medicare Part B drugs